<table sstyle="width:80%" align="center" border=1>
<tr>
<th>mv</th>
<th>dw</th>
<th>HMMCrowd</th>
</tr>
<tr>
<td width=33%>
[139, 157] pain, anorexia, diarrhoea, fatigue, nausea and vomiting, dyspnea, constipation and insomnia)<br>[244, 246] median survival<br></td>
<td width=33%>
[110, 125] European Organisation for Research and Treatment of Cancer Quality of Life (EORTC QOL)-C30 questionnaire<br>[138, 157] (pain, anorexia, diarrhoea, fatigue, nausea and vomiting, dyspnea, constipation and insomnia)<br>[184, 188] EORTC QOL-30 questionnaire.<br>[193, 197] median time to progression<br>[244, 246] median survival<br></td>
<td width=33%>
[48, 52] advanced epithelial ovarian cancer<br>[110, 125] European Organisation for Research and Treatment of Cancer Quality of Life (EORTC QOL)-C30 questionnaire<br>[138, 157] (pain, anorexia, diarrhoea, fatigue, nausea and vomiting, dyspnea, constipation and insomnia)<br>[184, 188] EORTC QOL-30 questionnaire.<br>[193, 197] median time to progression<br>[244, 246] median survival<br>[295, 299] comparable efficacy and survival<br>[306, 310] cumulative haematological toxicity.<br>[310, 314] Non-haematological toxicity<br>[325, 331] survival rate indicates substantial therapeutic benefit<br></td>
</tr>
